peptide specific dendritic cell

Phase 1Biologic

ZZhujiang Hospital

peptide specific dendritic cell is one of 48 biologic programs targeting Leukemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeukemiaRecruiting

LeukemiaPhase 1

Recruiting

Competition

Competitive Landscape

108 competitors in Leukemia

#DrugCompanyPhaseTrials

Cytosar

Teva

Phase 3

53 2

Trexall

Jazz Pharmaceuticals

Phase 3

30 3

Fludara

Sanofi

Phase 3

20 4

Rituxan

Roche

Phase 3

16 5

Cytoxan

BBaxter Healthcare Corporation

Phase 3

56 6

Adriamycin

Pfizer

Phase 3

11 7

Oncovin

Eli Lilly

Phase 3

10 8

Vepesid

AAvyxa

Phase 3

23 9

Decadron

AAspen Global Incorporated

Phase 3

23 10

Mesnex

BBaxter Healthcare Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Leukemia1 trial

CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS

Recruiting·ZZhujiang Hospital·Phase 1·NCT03291444·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for peptide specific dendritic cell. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — peptide specific dendritic cell compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for peptide specific dendritic cell. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhujiang Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: ZZhujiang Hospital

peptide specific dendritic cell

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Leukemia1 trial

References

Drug Info

Quick Facts

Related News